Reach Us +1-218-451-2974


Klaus Romero | OMICS International
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Klaus Romero

 CAMD Clinical Path Institute, USA


Dr. Klaus Romero is a clinical pharmacologist and epidemiologist. As an Assistant Professor of Pharmacology at the Colombian Military University and as an Instructor for the American Heart Association’s BLS, ACLS and ACLS-EP courses, Dr. Romero was also a clinical research consultant for Astra-Zeneca Colombia, and worked as a clinical pharmacologist for the CIEO Foundation, a non-profit organization, focused on drug safety research and pharmacovigilance in Colombia. In 2003 he planned, organized and implemented the Colombian National Police Health Services’ Pharmacovigilance system, still operating today. He is a fellow of the American College of Clinical Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has conducted research on endemic channels for non-steroidal anti-inflammatory drug-related gastropathy, antibiotic-related dysglycemia, drug-induced QT prolongation, pharmaco epidemiology and patient education. Dr. Romero has been with C-Path since January of 2008, where he has helped lead clinical pharmacology, pharmacoepidemiology and modeling and simulation projects for the Coalition Against Major Diseases, the Polycystic Kidney Disease Outcomes Consortium and the Critical Path to TB Drug Regimens Consortium, achieving major milestones such as the first regulatory endorsement by FDA and EMA of a clinical trial simulation tool for mild and moderate Alzheimer’s Disease. He is fluid in English, Spanish, German and Portuguese, and has published in the areas of clinical pharmacology, pharmaco metrics, cardiovascular drug safety and pharmaco epidemiology.

Research Interest

Clinical Pharmacology, non-steroidal anti-inflammatory drug-related gastropathy, antibiotic-related dysglycemia, clinical pharmacology, pharmacoepidemiology,